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Aron Fdmerman, Hylton L Miller. TeI Aviv Medical Center, Tel Aviv, Israel 
We have previously reported our expedence wtlh ultraso~d anglopfaaty in 
experimental and dinicat settings. These sit.as sug~e~ that ulVasound 
selectively ablates thrombi with a wide margin of safety. The purpose of this 
study is to evaluate, for Ille first time, the clinical fees~lity of percutaneous 
comnan] ultrasound thromb~lysis (ULTH) as the primary repeduslon ther- 
apy in acute myocardial infarction (MI). The uHresouP, d thmmbolysis device 
consists of a solid metal probe with a distal multi-wire flexible segment, cor~ 
nected to a 1,6 mm tip. The device fits into a 1 OF guiding calheter over 0,014" 
guidewtm. Eligible patients had acute anterior MI and TIMI 0-1 flow in the 
LAD, To date, ULTH was attempted in 6 consecutive patients (10ts). In 
first pt. ULTH failed. In the follOwing consecutive 5 pts, following a change in 
the technique, sonfcatton (45 kHz, 18 Watts. 3 m) induced TIMI grade 3 flow, 
MLD of 1.7 :J: 0.9 mm and residual stenosis of 45 ~ 24%. There were no 
dissections, perforations, embolizations or spasm. There were no adverse 
events during ULTH. Adjunct PTCA, employed in all pts, resulted in final MLD 
of 2.3 :J: 0.3 mm and residual atenosis of 12 :~ Ib'%. Repeat ang~ at 
10 rain and 24 hr revealed TIMI 3 flow in all pis. In.hospital, 1 Pt. developed 
acute closure on day 5 that was lmated successfully by PTCA. There were no 
deaths, bleeding or need for vascular repair. Conclusion: ULTH is potentially 
a safe and effective device solution for reperfusion therapy in the setting of ML 
~ lntracoronary Adenosine as an Adjunct to 
Combined Use of Primary Angioplacty in Acute 
Myocardial Infarction: Beneficial Eltects on 
Anglographically Assessed No-Reflow 
Made Merzilli, Peele M,~rracotni, End Gliozheni, Enrico Omini, 
Eugenio Pioa.o. CNR, Institute of Clinfcal Physiology. Plea, Italy 
A sound theoretical nd experimental framework exists to support he investi- 
gation of adenosine as an adjunct o reper~uslon therapy among humans with 
acute myocardial infarction. Aim of this pilot study was to evaluate the safety 
and feasibility of Inttacomnmy adenosine (ADO) dudng primary angiopissty, 
as well as its effects on anglographlually assessed "no-reffow" phenomenon, 
Of 40 pts with acute myocerdfal infarction cons~ mfan'ed for primary 
angioplasty0 20 (Group I) received intracoronsry ADO (4 mg over 4 minutes) 
and 20 intr~comnary saline (Group II). The 2 groups were similar for age (I 
= 61 :E 12 vs II ,= 65 :t: 10, p = ns), sex (females: I = 5/20 vs II = 2/10, p 
== ns), location of Infarct-related arteP/(left anterior descending I = 10/20 vs 
II = 12/20, p = ns), time from onset of chest pain to first dilatatton (I = 95 
:1= 59 vs tl 129d: 122 rain, p = ns). No pts hod,amrsantng of chest patn or 
hemodynamic instability or any other limiting side effects during either ADO 
or saline infusion. Following angk~faaty the 2 Groupa had a comperabh~ final 
residual stenosis (% diameter eduction I = 27.4- 11 vs II = 30:4: 12, p = ns), 
but TIMI grade (from 0 = no flow to 3 = norolal flow) in the infarot-mlatad 
artery was 2.7 4. 0.4 in Group I and 2,18 :E 1,25 in Group II (p < 0.01). 
Anglographlcally assessed no-inflow in the infar~t-m~ated artery was present 
in 0 out of 20 pis of Group I and in 6 out of 20 pts of Group II (0 vs 30%, 
p < 0.01). In patients with acute myocardial infarction intracomna~ ADO 
before pflmanj angioplasty is feasible and well tolerated, and is associated 
tO a lower incidence of angtographioally assessed no-fellow in the dilated 
infarct-related artery. 
~ T h e  Effects of Tissue Factor Pathway Inhibitor on 
Myocardial infarct Size 
Basem Koudsl, Edward W. Ferguson, Chester O. Yu, Gary A. Miller, Kurt 
D. Merkel, Tze-Chein Wun, Samuel R. Money, Bruce A, Kraemer. 
Washington University, St. Louis, MO 
Evidence is presented that a novel anticoagulant, Tissue Factor Pathway 
Inhibitor (TFPI), signlflcant~ reduces infarct size in a rabbit myocerdiom 
ischemia/mpeffusion (I/R) model. Recombinant TFPI was examined to de- 
termine its abitfly to enhance survival of jeopam'ized myoca,-dium following 
ischemic insult and repertuslon. Male and female New Zealand White Rab- 
bits were anesthetized, their circumflex artery was OCcluded for a period of 
45 minutes followed by a 3 hour mpeduslon period. In addition to a con- 
trol group (n = 11), two groups motived 10 cc of either TFPI (N = 11.200 
pg/ml) or vehicle (n = 10) infused over 10 seconds into the left atrium (I.A) 
at the onsof of mPedusien. Area at dsk (AAR) was dofen-nined by infusing 
Evans blue into the La, with the circumflex occluded; percentage of AAR 
eurviving was Idantified using oross sscl~ons of lhe left ventdcfe atalned with 
2,3,5-Triphenyl-tebazolium Chloride (TTC) and planimeby measurements, 
Area of necrosis (AN) eq0.~=d aS a percentage of AAR (AN/AAR) showed 
significant ddferances between the TFPI treated animals vs. those l t~ re* 
coived either vehicle or no drug (23.5% vs. 42.5% and 39.1%) respectively, 
p = 0.0006 and o.003). No sign,'¢ant d~erance was observed between the 
groupe with regard to AAR, total LV area or h '~-¢e  of d y s ~  These 
results demonstrate that in the rabbit model, TFPI is an effective agent in 
n~Jcing ~ myocardial in~rct size following isohemia mperfeslon in vivo 
and may prove to be a valuable addition to curmet treatments for acute 
myocerd~ iofa~clion. 
~ R i s k  Factors for Isehemic Stroke in Patients W'dh 
Acute Myocardial Infarction Treated With 
Thrombolyt ic Therapy 
Kenneth W. Mahaffey, Christopher B. Granger, Harvey D. White, Joel 
M. Gore, W. Douglas Weaver, Michael A. Sloan, Eric J. Topoi, Robert 
M. Califf, for the GUSTO Investigators. Duke Universe, Durham, NC 
To determine the factors assudated with ischemlo stroke in patients with 
asute rnyocerdiat infarction (AMI) tmatod with th ren~ therapy, we ana- 
lyzed the 247 (0.6%) patients with bland ischemio atmke in the GUSTO.I b'iat. 
Mortality was 17% and an ad(Mional 40% had moderate or ~ disablfity. 
VadaUes analyzed th.s far incieded amugmphlcs, dtn~at history and risk 
factors, ~ and trsatment ass@vnsm with the most important 
univariable relationships as follows: 
Palkml characteristic Unlvarleble x 2 Odds Ratio* 
O~er age (per 10 yearn) 86 I.? 
History o! stroke 26 4.3 
Diabetes 24 2.t 
Histo~/of hypertension 24 1,9 
Prior angina 24 2.0 
Higher pulse (per 10 beats) 20 1,2 
Prm'icus AMI 19 2,0 
Wame K~nip da~ (per d.ass) 1;' 0.6 
Cunenlsmo~er 16 0,6 
Prev~us bypa~ m~g~y 10 2.2 
Lower weight (per 10 ko) 8 0.8 
Female sex 5 0.7 
"Nip <0.05. 
Ischemlo stroke is an ~ complication I  ~ with AMI treated 
with thrombolysls, hepadn and aspidn but 57% of patients die or suffer 
disability. Risk facfum kn0wn to be essodated with mortality tn patients with 
AMI are also dsk factors for ischemie stroke, an important outcome to include 
in baseline risk assessmenL 
A CompoMte and Practical View of Standard 
CoagulaUon Monitodng in the Identification of 
Pmlento ct Risk for Meier Hemordmp 
Richard C. Becket, Chdatopher P. Cannon, Yunsheng Me, Thomas Hurley, 
James HeberL Thrombosis Research Center, Untvemily of Massachusetts 
MedP.alSchcot. Wo~r ,  MA 
An ability to identify patients likely to expeflanco major hemorrhage fol- 
lOWing thrombatytlc and ~ anticoagulant therapy is of paramount 
clinical importance. Patients par l~t ing in TIMI 5 (n = 246) received ac- 
ceisrated IPA and either hepedn (target aPTT 65--90 sac) or himdin (fixed 
dose), 
The probability of hemonhage increased 2% for each 1 sac increase in 
aPTT. By multhradable analysis, 12 h aPT'l" was independently associated 
with major hemenhage (p < 0.01), A 12 h aPTT _> 85 sac yielded esnsitivity, 
specificity, positive and negative predceve values of 73%, 53%, 23%° and 
90%. In condush~l, the standard aPTT measurement is a clinically useful 
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